

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE
(Attorney Docket No. 006420.00004)

**RECEIVED
CENTRAL FAX CENTER**

In the Application of:)
Dharmadhikari, et al.)
Serial No.: 10/526,285) Group Art Unit: 1614
Filed: March 2, 2005) Examiner: Grafeo, Michael
For: Pharmaceutical Composition of Metaxalone) Confirmation No.: 4683
With Enhanced Oral Bioavailability)

SUBMISSION OF JOINT DECLARATION FOR PATENT APPLICATION

**Mail Stop PCT
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450**

Sir,

Due to what Applicants believe was an inadvertent error by the Patent Office, a Notice of Missing Requirements Under 35 U.S.C. 371 in the United States Designated/Elected Office (DO/EO/US) was not mailed to Applicants regarding an executed Declaration. In order to make the record complete, Applicants hereby submit the enclosed executed Joint Declaration for Patent Application.

The Commissioner is authorized to debit the \$130.00 late filing surcharge fee from our Deposit Account No. 19-0733. The examiner is also authorized to charge any additional fees or credit any over payments to deposit account 19-0733 in connection with this filing.

Respectfully submitted,
BANNER & WITCOFF, LTD.

Dated: May 19, 2006

By:

Robert H. Resis
Reg. No. 32,168

05/23/2006 EFLORES 00000050 190733 10526285
01 EC-1051 130-00 DA

BANNER & WITCOPP, LTD.
TEN SOUTH WACKER DRIVE
CHICAGO, ILLINOIS 60606
TELEPHONE (312) 463-5000

Attorney Docket No. 006420.00004

JOINT DECLARATION FOR PATENT APPLICATION

As the below named inventors, we hereby declare that:

Our residence, post office address and citizenship are as stated below next to our names;

We believe we are the original, first and joint inventors of the subject matter which is claimed and for which a patent is sought on the invention entitled **PHARMACEUTICAL COMPOSITION OF METAXALONE WITH ENHANCED ORAL BIOAVAILABILITY**, the specification of which was filed on March 2, 2005 as Application Serial Application No. _____ and was amended on _____ (if applicable).

We hereby state that we have reviewed and understand the contents of the above-identified specification, including the claims, as amended by any amendment referred to above.

We hereby acknowledge the duty to disclose information which is material to patentability in accordance with Title 37, Code of Federal Regulations, §1.56(a).

Prior Foreign Application(s)

We hereby claim foreign priority benefits under Title 35, United States Code, §119 of any foreign application(s) for patent or inventor's certificate listed below and have also identified below any foreign application(s) for patent or inventor's certificate having a filing date before that of the application on which priority is claimed:

Country	Application No.	Date of Filing (day month year)	Date of Issue (day month year)	Priority Claimed Under 35 U.S.C. §119
India	790/MUM/2002	02-09-2002		X
PCT	PCT/IN03/000294	02-09-2003		X

Prior United States Provisional Application(s)

We hereby claim priority benefits under Title 35, United States Code, §119(e)(1) of any U.S. provisional application listed below:

U.S. Provisional Application No.	Date of Filing (day month year)	Priority Claimed Under 35 U.S.C. §119(e)(1)

Prior United States Application(s)

We hereby claim the benefit under Title 35, United States Code, §120 of any United States application(s) listed below and, insofar as the subject matter of each of the claims of this application is not disclosed in the prior United States application in the manner provided by the first paragraph of Title 35, United States Code, §112, we acknowledge the duty to disclose material information as defined in Title 37, Code of Federal Regulations, §1.56(a) which occurred between the filing date of the prior application and the national or PCT international filing date of this application:

Application Serial No.	Date of Filing (Day, Month, Year)	Status X Patented, Pending, Abandoned

Attorney Docket No. 006420.00004

All correspondence and telephone communications should be addressed to:

Banner & Witcoff, Ltd.
Customer Number: 22908

We hereby declare that all statements made herein of our own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code and that such willful false statements may jeopardize the validity of the application or any patent issuing thereon.

FIRST INVENTOR:

Full Name: DHARMADHIKARI, Nitin, Bhalechandra
 Citizenship: India
 Residence: c/o Sun Pharmaceutical Industries Ltd., 17/B Mahal Industrial Estate, Off. Mahakali Caves Road, Andheri (East), Mumbai 400 093, Maharashtra, India
 Post Office Address: c/o Sun Pharmaceutical Industries Ltd., 17/B Mahal Industrial Estate, Off. Mahakali Caves Road, Andheri (East), Mumbai 400 093, Maharashtra, India

Date: MARCH 31, 2005Signature: N.B.DhamadhiKari

SECOND INVENTOR:

Full Name: MUNGRE, Ashish Prabhakar
 Citizenship: India
 Residence: c/o Sun Pharmaceutical Industries Ltd., 17/B Mahal Industrial Estate, Off. Mahakali Caves Road, Andheri (East), Mumbai 400 093, Maharashtra, India
 Post Office Address: c/o Sun Pharmaceutical Industries Ltd., 17/B Mahal Industrial Estate, Off. Mahakali Caves Road, Andheri (East), Mumbai 400 093, Maharashtra, India

Date: MARCH 31, 2005Signature: Ashish Mungre

THIRD INVENTOR:

Full Name: ZALA, Yashoraj Rupsinh
 Citizenship: India
 Residence: c/o Sun Pharmaceutical Industries Ltd., 17/B Mahal Industrial Estate, Off. Mahakali Caves Road, Andheri (East), Mumbai 400 093, Maharashtra, India
 Post Office Address: c/o Sun Pharmaceutical Industries Ltd., 17/B Mahal Industrial Estate, Off. Mahakali Caves Road, Andheri (East), Mumbai 400 093, Maharashtra, India

Date: MARCH 31, 2005Signature: Yashoraj Zala